NCCN Guidelines for Patients® | Multiple Myeloma

35 NCCN Guidelines for Patients ® : Multiple Myeloma, 2018 3 Myeloma treatments Clinical trials † † Phase III trials compare a new drug to the standard treatment. † † Phase IV trials test new drugs approved by the FDA (U.S. F ood and D rug A dministration) in many patients with different types of cancer. Joining a clinical trial has benefits. First, you’ll have access to the most current cancer care. Second, you will receive the best management of care. Third, the results of your treatment—both good and bad—will be carefully tracked. Fourth, you may help other people who will have cancer in the future. Clinical trials have risks, too. Like any other test or treatment, there may be side effects. Also, new tests or treatments may not help. Another downside may be that paperwork or more trips to the hospital are needed. To join a clinical trial, you must meet the conditions of the study. Patients in a clinical trial often have a similar cancer type and general health. This is to know that any progress is because of the treatment and not because of differences between patients. To join, you’ll need to review and sign a paper called an informed consent form. This form describes the study in detail. The study’s risks and benefits should be described and may include others than those described above. Ask your treatment team if there is an open clinical trial that you can join. There may be clinical trials where you are getting treatment or at other treatment centers nearby. You can also find clinical trials through the websites listed in Part 5.

RkJQdWJsaXNoZXIy MTE3MTE1